Phase 1, first-in-human, single-/multiple-ascending dose study of iluzanebart in healthy volunteers

Authors

• Andreas Meier, Formerly Vigil Neuroscience, Inc.
• Spyros Papapetropoulos, Formerly Vigil Neuroscience, Inc.
• Andrew Marsh, Formerly Vigil Neuroscience, Inc.
• Kelly Neelon, Formerly Vigil Neuroscience, Inc.
• David Stiles, Formerly Vigil Neuroscience, Inc.
• Ryan O'Mara, Vigil Neuroscience, Inc.
• Evan A Thackaberry, Vigil Neuroscience, Inc.
• Marco Colonna, Washington University School of Medicine in St. Louis
• Raj Rajagovindan, Formerly Vigil Neuroscience, Inc.

Journal

Annals of Clinical and Translational Neurology

Publication Date

5-1-2025

Volume

12

Issue

5

First Page

1065

Last Page

1076

Document Type

Open Access Publication

DOI

10.1002/acn3.70033

Rights and Permissions

Meier, A., Papapetropoulos, S., Marsh, A., Neelon, K., Stiles, D., O'Mara, R., Thackaberry, E.A., Colonna, M. and Rajagovindan, R. (2025), Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers. Ann Clin Transl Neurol, 12: 1065-1076. https://doi.org/10.1002/acn3.70033 © 2025 Vigil Neuroscience. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Meier, Andreas; Papapetropoulos, Spyros; Marsh, Andrew; Neelon, Kelly; Stiles, David; O'Mara, Ryan; Thackaberry, Evan A; Colonna, Marco; and Rajagovindan, Raj, "Phase 1, first-in-human, single-/multiple-ascending dose study of iluzanebart in healthy volunteers." Annals of Clinical and Translational Neurology. 12, 5. 1065 - 1076. (2025).
https://digitalcommons.wustl.edu/oa_4/7004

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.